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Background: BR.21 is a double-blind, placebo-controlled trial of
second-/third-line erlotinib in stage IIIB/IV non-small cell lung
cancer patients. Predictive and prognostic analyses of epidermal
growth factor receptor (EGFR), ABCG2, and AKT1 genetic poly-
morphisms were performed.
Methods: Two hundred forty-two patients were genotyped for EGFR-
216GT (EGFR216), EGFR-191CA (EGFR191), EGFR intron 1
CA-dinucleotide-repeat (CADR), ABCG2421CA (ABCG2), and
AKT1-SNP4GA (AKT1). Cox proportional hazard and logistic regres-
sion models compared genotypes with overall survival (OS), progres-
sion-free survival (PFS), and presence/absence of skin toxicity.
Results: Prognostic evaluation was based on the placebo arm:
patients carrying at least one CADR long allele (16 repeats) had a
trend toward worse PFS: the adjusted hazard ratio was 1.7 (95%
confidence interval [CI]: 1.0–3.0; p  0.07). EGFR216, EGFR191,
ABCG2, and AKT1 were not prognostic. Polymorphisms were not
predictive for erlotinib effect (OS/PFS): no treatment-polymorphism
interactions were demonstrated. Individuals carrying the rare T/T
genotype of EGFR216 had an adjusted odds ratio of 8.8 (95% CI:
1.1–72; p  0.04) of developing skin toxicity; no other significant
polymorphic relationships with skin toxicity were found.
Conclusions: In contrast to previous publications, carrying shorter
alleles of the EGFR CADR polymorphism was not predictive of OS
or PFS. EGFR216 homozygous variants were associated with
greater skin toxicity from erlotinib.
Key Words: Genetic polymorphism, Clinical trial, Pharmacogenet-
ics, Survival, Toxicity.
(J Thorac Oncol. 2012;7: 316–322)
Germline polymorphisms have been reported to be associ-ated with efficacy or toxicity of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs). The EGFR
gene contains numerous polymorphic variants; several are asso-
ciated with putative functional consequences: (i) the EGFR-
216GT (EGFR-216) and the EGFR-191CA (EGFR-191)
promoter polymorphisms are located in the transcriptional start
site region of the EGFR promoter and may alter mRNA gene
expression1,2; (ii) an EGFR dinucleotide CA repeat sequence
polymorphism (CADR) located in the intron 1 gene enhancer
region ranges from 14 to 22 repeats, with the most common
allele being 16 repeats3–5; shorter alleles have been associated
with greater EGFR protein expression5,6; and (iii) A codon 497
polymorphism producing an arginine-to-lysine substitution also
has been associated with improved survival and greater skin
toxicity in patients treated with EGFR monoclonal antibodies in
colorectal cancer7 but not in EGFR-TKI-treated patients. Several
groups have described putative predictive associations between
either EGFR CADR or promoter polymorphisms and response,
survival, or toxicity.8–12 Dubey et al.13 suggest that some of
these polymorphisms are actually prognostic. Other potentially
predictive polymorphisms include those of the drug transporter
ABCG2, which has been shown to be active in removing
gefitinib from the cell; ABCG2 polymorphisms have been asso-
ciated with both gefitinib and erlotinib treatment outcomes.14–17
Higher phospho-AKT has been associated with less erlotinib-
inducing rash,18 whereas the A/A genotype of AKT1-SNP4
(AKT2) has been associated with the lack of response to ge-
fitinib19; an association between AKT1 polymorphisms and er-
lotinib outcome has not been described.
The purpose of this analysis was to explore (i) the
potential prognostic role of pharmacogenetic polymorphic
variants in the placebo arm of BR.2120 and (ii) their predic-
tive roles in determining efficacy/survival or skin toxicity in
patients treated with erlotinib versus placebo.
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PATIENTS AND METHODS
Sample Description
Research ethics board approval was obtained at the Uni-
versity Health Network. Figure 1 summarizes the flow of bio-
specimens obtained from the NCIC CTG tissue bank (Kingston,
ON). Samples were formalin-fixed paraffin-embedded (FFPE)
in the form of tumor blocks or slides. Sixty-one percent (n 170
erlotinib arm, n 93 placebo arm, and n 263 total) of the 431
patients whose slides or blocks were originally sent to NCIC
CTG central tissue repository had available tissue for the present
analysis. Of these, 242 of 263 (92%) were successfully geno-
typed for one or more of the genetic polymorphisms. Of these,
156 came from patients receiving erlotinib, whereas 86 were
from placebo cases. These 242 patients formed the polymor-
phism-assessed (PA) cohort.
All other individuals in the trial were considered part of
the non-PA group, which comprised 39% of all cases in
which tumor biospecimens had been collected as part of the
original trial. Mutational, gene copy number, gene expres-
sion, and immunohistochemical testing in published analyses
had used up 31% of specimens such that none were available
for genotyping. In another 8% of patients whose slides or
blocks had been collected, the remaining tissue was deemed
too little for analysis.
DNA Extraction and Genotyping
Before examining the BR.21 specimens, matched
FFPE-derived tumor and fresh lymphocyte-derived DNA
were obtained from non-small cell lung cancer (NSCLC)
patients from Princess Margaret Hospital and were compared
for their genotyping concordance in each polymorphism.
For the BR.21 specimens, the laboratory was blinded to
treatment arm allocation and patient identity. DNA was
extracted as described.21 The polymorphisms, EGFR-216
(rs712829), EGFR-191 (rs712830), EGFR CADR, ABCG2
(rs2231142), and AKT1 (rs1130233), were genotyped, de-
tailed in Appendix 1. We excluded the analysis of the ABCG2
34GA (V12M, rs2231137) polymorphism17 because it had a
2% minor allele frequency in our Caucasian-predominant
population. Because of the lack of remaining DNA, the
EGFR codon 497 polymorphism was not assessed, as this
polymorphism had only been associated with the outcome in
patients treated with monoclonal antibodies targeting EGFR
and not in EGFR-treated patients.
Clinical Outcomes
Response was assessed by the RECIST 1.1, whereas
toxic effects were assessed according to the Common Tox-
icity Criteria of the National Cancer Institute (version 2.0).20
Overall survival (OS) was defined as the time from random-
ization to date of death. Progression-free survival (PFS) was
defined as the time from randomization to date of progression
or death from any cause, whichever came first. All grades of
skin toxicity were considered together; in the original trial,
only 1.9% of individuals in the erlotinib arm and 0% in the
placebo arm had skin toxicity of grades 3 or higher.
Statistical Methods
All genotyping results were sent to NCIC CTG for
incorporation into the BR.21 trial database. All statistical
analyses were conducted by NCIC CTG. Baseline demo-
graphic, clinical information, and survival outcome were
compared between individuals with samples available for
pharmacogenetic analysis (PA cohort) and those without
(non-PA cohort). Within individuals with genotyping data,
demographic and clinical information was compared across
genotypes using Fisher’s exact test (for categorical variables)
and Kruskal–Wallis test (for continuous variables). All pri-
mary models assumed codominant genetic inheritance mod-
els; secondary models evaluated the additional inheritance
models reported from the prior literature specifically for the
outcome/toxicity previously studied.
Logistic regression was used to investigate predictors
of skin toxicity. Cox proportional hazards regression and the
log-rank test were used to compare survival (PFS and OS).
Multivariate models were constructed with pharmacogenetic
data (i.e., polymorphisms) after adjusting for individual co-
variates found to be predictive of survival or toxicity out-
comes (at the p  0.10 level). Survival estimation was
performed using the Kaplan–Meier method. All statistical
testing was two-sided with an  error defined at a 0.05 level
of significance, and SAS software version 9.1 (SAS Institute
Inc., Cary, NC) was used. Likelihood ratio tests (LRTs; set at
  0.05) compared models to determine whether the addi-
tion of the genetic polymorphism to the base model resulted
in significance.
FIGURE 1. Biospecimens available and analyzed from BR.21
trial. Samples were not available for release because the
samples either had been used up in prior translational analy-
ses (e.g., mutational analysis, in situ hybridization, immuno-
histochemical analysis, and gene expression analyses) or
were deemed to have inadequate remaining tissue for the
present analysis. Most of these samples were from cases in
which slides (rather than blocks) had been provided by the
originating pathology department. Failed genotyping refers
to failure of the genotyped result to meet quality control
standard, including failure of replication during duplicate
genotyping or uninterpretable genotyping results despite
repeated testing.
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RESULTS
Baseline Clinical Characteristics
Baseline clinical characteristics for the PA and non-PA
cohorts are compared in Table 1. There were major differ-
ences in demographic and clinical characteristics between the
two cohorts: the non-PA cohort had relatively more Asian
patients, had experienced better response to prior therapies,
the non-PA cohort were more likely to have two or more prior
treatment regimens, and had longer time from diagnosis to
randomization (p  0.01 for each comparison). Despite these
differences, the two cohorts had similar OS and PFS and
benefited similarly from study treatment (test of homogeneity
for the interaction between treatment arm and availability of
biospecimens, p 0.89). The adjusted hazard ratio (aHR) for
the benefit of erlotinib in the PA cohort was 0.78 (0.6–1.1),
whereas the aHR was 0.75 (0.6–0.9) for the non-PA cohort.
Baseline Genotyping Characteristics
Before investigating the BR.21 specimens, it was im-
portant to determine whether our polymorphisms were found
in genomic regions representing hotspots for loss of heterozy-
gosity and genomic instability, because the analysis assessed
tumor DNA as a surrogate for germline DNA. DNA derived
from FFPE lung cancer biopsies from 30 patients with met-
astatic NSCLCs was compared with the matched lympho-
cyte-derived DNA (standard procedure) obtained from the
same individuals. Genotyping concordance rates were more
than 93% between normal and corresponding tumor tissue
DNA for each of the polymorphisms.
Because of decreasing material available for genotyp-
ing, the following are the number of individuals where
genotyping was attempted: EGFR CADR, n  242; EGFR-
216 and EGFR-191, n  151; ABCG2, n  200; and AKT1
genotyping, n  184. Genotyping success rates were 100%
for EGFR CADR, 95% for EGFR-216 and EGRR-191 geno-
typing, 96% for ABCG2, and 93% for AKT1.
Prognostic Associations
The potential prognostic significance of these polymor-
phisms was evaluated in the placebo arm. None of the polymor-
phisms were significantly prognostic for OS (Table 2), after
adjustment for other known prognostic factors (weight loss,
Eastern Cooperative Oncology Group performance status,
EGFR mutation status, and number of prior therapies). How-
ever, EGFR CADR demonstrated a trend to significance (aHR
was 1.7 [95% CI: 1.0–3.1; p  0.07]), whereby the longer
alleles were associated with poorer PFS.
Predictive Associations
Predictive models were adjusted for weight loss, East-
ern Cooperative Oncology Group (ECOG) performance sta-
tus, EGFR status by immunohistochemistry, and response to
prior therapies. There was no interaction between each of the
five polymorphisms and erlotinib treatment for either OS or
PFS (Table 3). There was a global trend toward significance
for the interactions between the ABCG2 and erlotinib treat-
ment (LRT, p  0.06), which was driven solely by the
ABCG2 A/A-treatment interaction term (p  0.01) that was
TABLE 1. Comparing Baseline Factors between Individuals
Who Did and Did Not Have an Available Biological Sample
for Pharmacogenetic Analysis
Variable
Biological Sample Available
for Analysis (%) p Value
Comparing
GroupsaNo (n  489) Yes (n  242)
Gender
Male 66 64 0.59
Female 34 36
Age
Age 60 or under 47 43 0.35
Over 60 yr 53 57
Performance status
ECOG 0 or 1 67 66 0.75
ECOG 2 or 3 33 34
Histology
Adenocarcinoma 48 54 0.15
Other 52 46
Weight lossb
Less than 5% 68 63 0.37
5% or more 28 31
Race
East Asian 16 6 0.001
Others 84 94
Smokingb
Never smoker 19 21 0.64
Ever smoker 74 76
Best response
Progressive disease 25 12 0.001
Stable disease 36 45
Partial disease/complete
response
39 43
Prior regimen
One 47 57 0.006
Two or more 53 43
Prior platinum
Yes 93 93 0.89
No 7 7
Time between diagnosis
and randomization
12 mo or under 51 38 0.001
More than 12 mo 49 62
EGFR mutation statusc
Present 0.4 18 0.62d
Absent 2 60
Uninterpretable 0 17
Missing 98 5
EGFR immunohisto
chemistryc
Positive 11 54 0.34d
Negative 7 44
Uninterpretable 9 2
Missing 73 0
a Missing data are not included in comparison.
b Percentages do not add up to 100% because of missing data.
c The denominator for this comparison was all individuals who had such a test performed.
d Comparison after excluding those with uninterpretable or missing data.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
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based on four patients carrying the A/A genotype (two pa-
tients in each treatment arm). Although the LRTs were not
statistically significant (p  0.14 and 0.27 for OS and PFS,
respectively), there was not a significant trend toward an
interaction between AKT G/A and treatment arm for both OS
(p  0.06) and PFS (p  0.11).
Association between Polymorphisms and Rash
Of the patients treated with erlotinib, 79% reported at
least grade 1 rash. None of the polymorphisms were globally
significantly associated with skin toxicity (Table 4). How-
ever, prior literature suggests that the association between
EGFR-216 polymorphism and rash was limited to the T/T
genotype. For the same comparison in BR.21, the adjusted
odds ratio for developing rash was 8.8 (95% CI: 1.1–72) in
patients who carried the T/T genotype, compared with the
G/G genotype (p  0.04). In the case of ABCG2, there was a
TABLE 2. Prognostic Association between Pharmacogenetic Polymorphisms and
Survival Outcomes (Placebo Arm)
Polymorphism
Adjusted Hazard Ratios (95% Confidence Intervals)
Likelihood Ratio Test p Values
Overall Survival Progression-Free Survival
CADR
L/L vs S/- 1.3 (0.7–2.5) p  0.43 1.7 (1.0–3.1) p  0.07
EGFR-216
G/T vs G/G 1.1 (0.5–2.2) p  0.98 1.0 (0.5–1.9) p  0.55
T/T vs G/G 1.0 (0.5–2.1) 0.9 (0.5–1.6)
EGFR-191
C/A vs C/C 1.0 (0.4–2.7) p  0.97 0.8 (0.4–1.7) p  0.78
A/A vs C/C 1.2 (0.3–5.0) 1.8 (0.6–6.0)
ABCG2
C/A vs C/C 0.2 (0.0–1.9) p  0.30 0.3 (0.0–3.3) p  0.09
A/A vs C/C 0.9 (0.2–4.1) 1.1 (0.2–5.9)
AKT1
G/A vs G/G 0.6 (0.4–1.5) p  0.47 0.7 (0.4–1.3) p  0.26
A/A vs G/G 1.0 (0.5–2.2) 0.5 (0.3–1.2)
EGFR-216, EGFR-216GT; EGFR-191, EGFR-191CA; CADR, EGFR intron 1 CA dinucleotide repeat; ABCG2,
ABCG2421CA; AKT1, AKT1-SNP4GA.
TABLE 3. Predictive Association between Pharmacogenetic
Polymorphisms and Survival Outcomes (Interaction Analysis)
Polymorphism
Poymorphism-Treatment Arm Interaction p
Values and Likelihood Ratio Test (LRT) p Values
Overall Survival
Progression-Free
Survival
Interaction LRT Interaction LRT
CADR
L/L vs S/- 0.92 0.92a 0.76 0.76a
EGFR-216
G/T vs G/G 0.28 0.47 0.60 0.48
T/T vs G/G 0.93 0.22
EGFR-191
C/A vs C/C 0.54 0.82 0.64 0.61
A/A vs C/C 0.95 0.33
ABCG2
C/A vs C/C 0.55 0.34 0.67 0.06
A/A vs C/C 0.16 0.01
AKT1
G/A vs G/G 0.06 0.14 0.11 0.27
A/A vs G/G 0.93 0.80
a The likelihood ratio test p value is equivalent to the interaction p value for these
comparisons.
EGFR-216, EGFR-216GT; EGFR-191, EGFR-191CA; CADR, EGFR intron 1
CA dinucleotide repeat; ABCG2, ABCG2421CA; AKT1, AKT1-SNP4GA.
TABLE 4. Predictive Association between Pharmacogenetic
Polymorphisms and Skin Toxicity (Treatment Arm)
Polymorphism
Adjusted Odds Ratios for Skin
Toxicity and Likelihood Ratio Test
(LRT) p Values
CADR
L/L vs S/- 0.6 (0.2–1.9) p  0.34
EGFR-216
G/T vs G/G 2.0 (0.5–8.3) p  0.13
T/T vs G/G 8.8 (1.1–72)
EGFR-191
C/A vs C/C 1.0 (0.1–6.8) p  1.00
A/A vs C/C 0.9 (0.2–5.8)
ABCG2
C/A vs C/C 0.9 (0.2–4.3) p  0.10
A/A vs C/C 0.04 (0.0–0.7)
AKT1
G/A vs G/G 0.7 (0.2–2.4) p  0.77
A/A vs G/G 0.6 (0.1–2.9)
EGFR-216, EGFR-216GT; EGFR-191, EGFR-191CA; CADR, EGFR intron 1
CA dinucleotide repeat; ABCG2, ABCG2421CA; AKT1, AKT1-SNP4GA.
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trend for the A/A genotype associated with significantly lower
risk of rash, when compared with the reference G/G genotype.
DISCUSSION
We did not confirm the significant prognostic or predic-
tive relationships between EGFR, ABCG2, and AKT1 polymor-
phisms found in previously reported hypothesis-generating stud-
ies,8–12,14,15,17,19 which are reviewed in the study by Horgan et
al.22 We did confirm a prior reported association8 between the
T/T genotype of the EGFR-216 polymorphism and increased
skin toxicity. Previous studies have demonstrated associations
between EGFR, ABCG2, or AKT1 polymorphisms and survival
or response in patients treated with EGFR-TKIs.8–12,19 Although
most studies included no control (untreated) patient group, a few
studies did include a case series of untreated patients. The result
were contradictory, with one study showing no association,8
whereas another described potential prognostic relationships in
untreated patients.11
Understanding the prognostic importance of a marker is
critical before trying to interpret its predictive value: if there
is a strong prognostic effect, single-arm studies may wrongly
interpret different survival outcomes as being due to the
predictive value of the biomarker rather than its prognostic
value. In BR.21, the presence of a randomized placebo-
controlled arm firmly led to the conclusion that none of the
polymorphic markers in this analysis were predictive.
Rash is not only the most frequent toxicity of erlotinib
(76% in erlotinib arm developed rash versus 17% in placebo
arm), but it is also associated with the primary end point of
OS in BR.21 (aHR  0.36 [95% CI: 0.3–0.5]).23 In particu-
lar, lack of rash resulted in a median survival of 3.2 months,
compared with 6.7 months for all erlotinib-treated patients.23
In the pharmacogenetic analysis, an association was found
between the EGFR-216T/T genotype and increased skin tox-
icity, which was almost exclusively grade 1 or 2. These
results are consistent with prior results in lung cancer pa-
tients.8 In contrast, the results from a study involving multiple
tumor types had conflicting results.17
The strengths of this study include (i) the use of data
from a randomized clinical trial that would allow optimal
determination of whether associations truly were pharmacoge-
netic predictive markers (i.e., associated with erlotinib therapy)
or whether the associations were primarily prognostic in nature
(i.e., not associated with treatment) without bias from selection
of systemic therapy; (ii) the use of a placebo control group, thus
providing a pure control group that reduced reporting bias (for
toxicity measurements); (iii) administration of erlotinib as
monotherapy, thus minimizing confounding by the use of che-
motherapy or other concomitant agents; and (iv) there was
minimal crossover to other therapies after progression, thereby
allowing for robust survival analyses. There are no other large-
scale placebo-controlled erlotinib monotherapy studies available
for a pharmacogenetic analysis. For the polymorphisms evalu-
ated in BR.21, the high concordance in results (93%) between
tumor and blood (germline) derived DNA in our 30-patient
substudy suggests that the tumor DNA analyzed in this trial
serves as a reasonable surrogate for germline DNA in toxicity
analyses.
There are several limitations of this analysis. This phar-
macogenetic study was an unplanned subgroup analysis in the
select cohort of BR.21 trial patients that had available remaining
tissue specimens. The sample size and power of the study were
somewhat compromised by this lack of available biological
material. The subgroup with available tissue was less likely to be
Asian, more likely to have had only one prior regimen, had a
longer time from diagnosis to start of study drug therapy, but
were also less likely to develop progressive disease as the best
response to this drug. This represents a specific subset of mostly
Caucasian patients with slower growing disease and less prior
treatment (i.e., a better outcome subgroup of Caucasians). These
and other factors of external validity have been touted as poten-
tial reasons as to why polymorphism associations do not validate
across studies. How these associations may change or alter our
results, when compared with the overall demographic distribu-
tions of the clinical trial remain unclear. Fortunately for the
internal validity assessment, the pharmacogenetic patient subset
confirmed the main BR.21 clinical trial result that overall and
major subsets of patients each derived benefit from erlotinib.20
Not all worthwhile candidate polymorphisms could be
assessed, because of the limitations in tissue availability. A
recent study suggested that local inherited EGFR polymor-
phic haplotype structures may confer differential risk of
developing subsequent EGFR somatic mutations in a Taiwan-
ese population.24 Because of the differences in mutation
frequency and haplotype structures by race, and the relatively
lower EGFR mutation rates in our BR.21 population preclude
the confirmation of these putative relationships using our trial
specimens.
This trial attempted to validate the findings in erlotinib-
treated patients that were first described in gefitinib-treated
patients. Although gefitinib and erlotinib are in the same family
of EGFR-TKIs and other biomarkers are similar between these
two compounds,25 subtle drug differences may explain varia-
tions in the ability of genetic polymorphisms to predict the
outcome or toxicity. In particular, erlotinib is dosed closer to its
maximum tolerated dose, whereas gefitinib is dosed to a lower,
more theoretical “biologically active” dose.
In summary, previously described associations between
EGFR-216 or EGFR-191 polymorphisms and outcome were
not replicated in BR.21. A strong predictive effect on OS or
PFS for these polymorphisms on erlotinib therapy can be
excluded in the subset of patients included in our studies.
Because of the sample size limitations, modest effects cannot
be excluded; however, such modest effects are highly un-
likely to yield changes in clinical practice in advanced
NSCLC patients. The EGFR-216T/T genotype was strongly
predictive of rash, replicating a previous phase II gefitinib
study.8
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APPENDIX 1: GENOTYPING METHODS
EGFR CA Dinucleotide Polymorphism
This polymorphism was preamplified by polymerase
chain reaction (PCR) using fluorescently labeled forward and
unlabeled reverse primers from a 184-bp preamplified PCR
product
EGFR-CA-forward 5 TCA CAG CAA ACT TCT CCT
CAA A 3
EGFR-CA-reverse 5 TCA TGT TCT GTC TGCACA CTT G 3
Reaction conditions: 95°C for 4 minutes; 40 cycles at 95°C
for 35 seconds, 56°C for 35 seconds, and 72°C for 30
seconds; and 72°C for 30 minutes
followed by a nested PCR step. Nested PCR primers were as
follows:
EGFR-CA-FAM(F), 5FAM-TTG CTG TTT GAA GAA
TTT GAG C-3
EGFR-CA-reverse, 5 TCATGTTCTGTCTGCACACTTG 3
Reaction conditions: 95°C for 4 minutes; 40 cycles at 95°C
for 35 seconds, 56°C for 35 seconds, and 72°C for 30
seconds; and 72°C for 30 minutes
FAM-labeled nested PCR product was diluted 1:20,
and 1 l of diluted PCR product was mixed with 9 l of
Hi-Di Formamide (Applied Biosystems, Carlsbad, CA) plus
0.25 l Genescan 500 Rox size standard (Applied Biosys-
tems, Cat# 401734). The samples were denatured at 95°C for
5 minutes and cooled on ice for 2 minutes. They were then
subjected to capillary electrophoresis by using POP7 polymer
with an excitation wavelength of 494 nm and detection
wavelength of 522 nm on an ABI 31310xl genetic analyzer.
PCR product of 130 bp was designated as the 16CA repeat
genotype. Other different amplicon sizes were calculated
according to this 16CA-130 bp standard.
EGFR-216 and -191 Polymorphisms
PCR amplification of the target EGFR fragment. The
following are the primers for first-round PCR and nest PCR:
First-round PCR (200 bp): EGFR-216F 5 ATT CTC CTC
CTC CTC TGC TCC T 3 and EGFR-216R 5 GGG GCT
AGC TCG GGA CTC 3
Nest PCR (160 bp): EGFR-nest 5GCC TGG TCC CTC CTC
CTC 3 and EGFR-216R 5 GGG GCT AGC TCG GGA
CTC 3
PCR reaction was run by using Invitrogen Platinum TaqDNA
polymerase (Cat# 10966-018).
The reaction conditions for the first-round touchdown
PCR are 94°C for 3 minutes; 15 cycles at 94°C for 40
seconds, 35 seconds for each annealing temperature that
starts at 67°C and then decreases to 0.5°C after each cycle,
72°C for 35 seconds; and then 12 cycles at 94°C for 30
seconds, 60°C for 30 seconds, 72°C for 30 seconds; and then
72°C for 5 minutes.
The nested touchdown PCR reaction conditions are
94°C for 2.5 minutes; 13 cycles at 94°C for 30 seconds, 30
seconds for each annealing temperature that starts at 66°C
and then decreases to 0.5°C after each cycle, 72°C for 30
seconds; and then 15 cycles at 94°C for 30 seconds, 60°C for
30 seconds, 72°C for 30 seconds; and then 72°C for 5
minutes.
PCR Product Presequencing Clean-Up
The aim of this procedure is to clear the remaining
primers and deoxynucleotides in the final PCR solution,
which affects subsequent Sanger sequencing. Two en-
zymes, exonuclease I (Fermentas, Burlington, Ontario,
Canada) and FastAP thermosensitive akaline phosphatase
(Fermentas), were used to clear the target PCR product.
Clear-up reaction included 0.4 l (10u) of exonuclease I,
1 l (1u) of FastAP, 5 l of final PCR solution into a total
volume of 15 l 1 exonuclease reaction buffer. The
solution was kept at 37°C for 15 minutes and then inacti-
vated the enzymes at 85°C for 15 minutes. The cleared
PCR product was kept at 20°C until Sanger sequencing.
Sanger Sequencing
The cleared PCR solution was diluted 1:4. Then, for
each sample, 7 l of the diluted PCR product was mixed with
0.7 l (5 M) of sequencing primer (EGFR-seq, 5 CTC-
CTCCTCCCGCCCTGC 3). The sequencing result was an-
alyzed by FinchTV software (Geospiza Inc., Seattle, WA).
ABCG2 rs2231142 Polymorphism
Preamplification: ABCG2-310F, 5 AGA ACT GCA GGT
TCA TCA TTA GC 3; ABCG2-310R, 5 TCA GTT TTT
CCA CAT TAC CTT GG 3.
PCR product (310 bp): PCR: 95°C for 4 minutes; 35 cycles at
95°C for 30 seconds, 20°C for 30 seconds, and 72°C for 30
seconds; and 72°C for 5 minutes.
Taqman assay (5 l for each sample): absolute QPCR mix
(2) 2.5 l (Thermo Scientific, Nepean, Ontario, Canada),
ABCG2 Taqman assay solution 0.125 l (40) (ABI, Cat#
C-15854163-70), and ddH2O 1.375 l and DNA template
1 l. Reaction conditions: 95°C for 10 minutes; 40 cycles
at 92°C for 15 seconds and 60°C for 1.5 minutes.
AKT1 rs1130233
Preamplification: Forward, AKT1-300-F, 5 TAG GGC TTC
TGA GAC TTT CCA G 3; reverse, AKT1-300-R, 5 CTT
GTC CAG CAT GAG GTT CTC 3.
PCR product is 300 bp: reaction conditions: 95°C for 4
minutes; 35 cycles at 95°C for 30 seconds, 56°C for 30
seconds, and 72°C for 30 seconds; and 72°C for 5 minutes.
Taqman assay: Reaction volume is 5 l: absolute QPCR mix
(2) 2.5 l (Thermo Scientific, Cat# AB-1139), ABCG2
Taqman assay solution 0.125 l (40) (ABI, Cat#
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C-7489835-10), and ddH2O 1.375 L and DNA template
1 l. Reaction conditions: 95°C for 10 minutes; 40 cycles
at 92°C for 15 seconds and 60°C for 1 minute.
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